Me gene privacy question takes a turn in bankruptcy Why a big AI player wants a quarter-million bucks from 23andMe Why a big ...

Regeneron develops new medicines and it rang up $3.7 billion in sales for its anti-inflammatory drug Dupixent as a treatment for eczema, asthma and chronic obstructive pulmonary disease, in its latest ...

DB-OTO, which Regeneron obtained from the 2023 acquisition of Decibel Therapeutics for $109 million, works by delivering a ...

With pricing reforms and PBM overhauls looming, pharma investors need to differentiate between companies that can absorb ...

Regeneron (REGN) stock was upgraded to Buy and AbbVie (ABBV) stock was downgraded at Citi based on policy risks under Trump's drug reforms. Read more here.

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Berlin: Bayer has submitted an application to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval of ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently reported earnings for Q1 2025 with a revenue drop to $3,029 million compared to the prior year, though net income increased, reflecting robust ...

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where ...

We recently compiled a list of the 10 Jim Cramer Stocks with Huge Upside Potential. In this article, we are going to take a ...

When a stock falls steadily on no news, that is a hint to avoid the company. Organon (OGN), a spin-off from Merck (MRK), continued to trade at a discount after posting results. The firm cut its ...